Kit Yu Lu, MD, discussed the implications of the TROPiCS-02 and DESTINY-Breast06 trial data for sequencing ADCs in HR+/HER2– breast cancer.
Kit Yu Lu, MD
Advertisement
Articles by Kit Yu Lu, MD
Currently, sacituzumab govitecan, T-DXd, and Dato-DXd cannot be compared in HR+/HER2– breast cancer due to a lack of head-to-head trials.
Kit Yu Lu, MD, identifies patients with HR+/HER2– metastatic breast cancer who may benefit from earlier T-DXd or sacituzumab govitecan treatment.
Advertisement
Latest Updated Articles
Navigating Treatment/Testing Decisions in Metastatic HR+/HER2– Breast CancerPublished: May 20th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Pembrolizumab/Enfortumab Vedotin in Muscle Invasive Bladder Cancer
2
How ADCs and BiTEs Are Propelling Change in Lung Cancer
3
Examining Neoadjuvant Chemoimmunotherapy Benefit in Stage III Lung Cancers
4
Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors
5
